Ubrelvy (ubrogepant) is a prescription drug that treats migraine episodes. This drug can interact with certain other medications and some supplements. For example, Ubrelvy can interact with ...
In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...
Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...
Neuroscience sales are likely to have been driven by the depression drug Vraylar and new migraine drugs — Ubrelvy and Qulipta. In November, AbbVie gained approval for Vyalev, a transformative ...
Zacks.com on MSN2d
AbbVie Q4 Earnings Loom: Buy or Sell ABBV Stock Ahead of Results?AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks ...
In the ad for oral CGRP inhibitor Ubrelvy (ubrogepant), Williams is depicted as suffering from a migraine while in a talk show dressing room, which resolves by the time she walks onto the set and ...
Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback